AstraZeneca Annual Report and Form 20-F Information 2011

More documents

Recommendations

Info

Therapy Area ReviewInfectionTherapy area world market(MAT/Q3/11) ($bn)13.812.040.0Market sectorsAnti-bacterialsAnti-viralsVaccinesOthers25.4$91.2bnThe world infection market is valued at $91.2 billion, withanti-bacterials accounting for approximately 44%, anti-viralsfor 28% and vaccines 15%.In brief> Synagis sales of $975 million; in the US $570 million, down 12%.> Merrem/Meronem sales of $583 million, down 30%.> FluMist sales of $161 million, down 7%.> In February 2011, the European Commission granted marketingauthorisation for Fluenz, a nasally administered live attenuatedinfluenza vaccine, for the prevention of seasonal influenza forchildren 24 months to less than 18 years of age. EU launches areplanned for the 2012/2013 influenza season.Our marketed productsRespiratory syncytial virus (RSV)> Synagis (palivizumab) is a humanised MAb used for theprevention of serious lower respiratory tract disease caused byRSV in paediatric patients at high risk of acquiring RSV disease.Serious bacterial infections> Merrem/Meronem 1 (meropenem) is a carbapenem antibacterialused for the treatment of serious infections inhospitalised patients.> Cubicin 2 (daptomycin) is a cyclic lipopeptide 00 anti-bacterialused for the treatment of serious infections in hospitalisedpatients.Influenza virus00> FluMist/Fluenz (influenza vaccine live, intranasal) is an intranasallive, attenuated, trivalent influenza vaccine.1Licensed from Dainippon Sumitomo.2Licensed from Cubist Pharmaceuticals, Inc.00Our financial performance2011ReportedSales growth$m %World US Western Europe Established ROW Emerging Markets Prior yearCERgrowth%ReportedSales growth$m %ReportedSales growth$m %CERgrowth%ReportedSales growth$m %CERgrowth%ReportedSales growth$m %Synagis 975 (6) (6) 570 (12) 404 3 3 – – – 1 – – 1,038Merrem/583 (29) (30) 41 (68) 179 (45) (48) 53 (7) (14) 310 2 – 817MeronemFluMist 161 (7) (7) 160 (8) – – – – – – 1 – – 174Non Seasonal Flu 7 (82) (82) 7 (82) – – – – – – – – – 39Others 130 19 17 70 3 10 n/m n/m 20 – (25) 30 55 90 108Total 1,856 (15) (15) 848 (19) 593 (18) (19) 73 (5) (17) 342 5 6 2,176CERgrowth%Worldsales$m2010Synagis 1,038 (4) (4) 646 (17) 392 31 31 – – – – – – 1,082Merrem/817 (6) (7) 127 (28) 328 (9) (7) 57 10 (4) 305 8 4 872MeronemFluMist 174 20 20 173 19 – – – – – – 1 – – 145Non Seasonal Flu 39 (90) (90) 39 (90) – – – – – – – – – 389Others 108 (24) (25) 68 (16) – (100) (93) 20 (5) (43) 20 54 92 143Total 2,176 (17) (18) 1,053 (33) 720 4 6 77 5 (15) 326 11 8 2,63164 Therapy Area Review InfectionAstraZeneca Annual Report and Form 20-F Information 2011
Our strategic objectivesWe aim to build a leading franchise in the treatment of infectiousdiseases through continued commercialisation of brands such asSynagis, Merrem/Meronem, FluMist/Fluenz and Cubicin, as wellas through the development of pipeline products such as Zinforo(ceftaroline). We also aim to make effective use of our structural andgenomic-based discovery technologies and antibody platforms,vaccines and continued small molecule and biologics research intonovel approaches in areas of unmet medical needs. Complementingour biologics capabilities, we are actively evaluating and integratingsmall molecule anti-RSV and anti-influenza basic research into ouroverall anti-viral approach.Respiratory syncytial virusApproximately half of all infants are infected with RSV during the firstyear of life and nearly all children in the US have been infected by thetime they reach their second birthday. RSV is the most common virusthat causes lung and airway infections in infants and young children.Premature babies (earlier than 36 weeks gestational age, especiallythose less than 32 weeks) and babies with chronic lung disease orcongenital heart disease are at increased risk of contracting severeRSV disease than full-term healthy babies.Our focusOur key marketed productsSynagis is used for the prevention of serious lower respiratorytract disease caused by RSV in children at high risk of the disease.It was the first MAb approved in the US for an infectious diseaseand has become the global standard of care for RSV prevention.Approved in 81 countries worldwide, Synagis remains the onlyimmunoprophylaxis in the marketplace indicated for the preventionof RSV in paediatric patients at high risk of RSV. Synagis isadministered by intra-muscular injection.In the pipelineWe are developing a live intranasal vaccine for the prevention of lowerrespiratory tract illness caused by RSV in otherwise healthy infants.Two vaccine candidates are in clinical development MEDI-559 andMEDI-534.Serious bacterial infectionsWorld demand for antibiotics and novel therapeutic approachesremains high and will continue to grow due to escalating resistanceand the increased risk of serious infections in both immunosuppressedpatients and ageing populations. Many bacterial infectionscurrently have few satisfactory treatment options prompting demandfor new and better therapies.Our focusOur key marketed productsMerrem/Meronem remains the leading carbapenem anti-bacterialacross a significant number of AstraZeneca’s licensed territories inwhich it is sold, except for the US (36% value share of the carbapenemmarket). Merrem/Meronem maintains a 6% share of the globalintravenous antibiotic market (by value), despite experiencing loss ofUS market exclusivity in June 2010. Continued generic growth acrossthe carbapenem class is anticipated over the next 12 months followingthe launches of numerous generics across Europe and the US.Cubicin is used for the treatment of serious gram-positive infectionsin hospitalised patients and is sold by AstraZeneca in selected territoriesin Asia, Europe and the Middle East. Cubicin was submitted formarketing approval by the SFDA in China in September for theadditional indication of complicated skin and skin structure infections.In the pipelineZinforo (ceftaroline) is a novel injectable cephalosporin, which is beingdeveloped in collaboration with Forest. Zinforo is effective againstgram-positive organisms and commonly susceptible gram-negativeorganisms associated with community-acquired pneumonia (CAP)and complicated skin and soft tissue infections (CSSTI). In particular,Zinforo is active against methicillin-resistant staphylococcus aureus(MRSA). Forest received FDA approval for ceftaroline in October 2010in the US for the treatment of acute bacterial skin and skin structureinfections and community-acquired bacterial pneumonia caused bydesignated susceptible bacteria. Forest launched in March 2011 underthe brand name Teflaro (ceftaroline). AstraZeneca is responsible forregistration and marketing outside the US, Canada and Japan andfiled an MAA for the 27 member states of the EU in December 2010.Further submissions in other jurisdictions continued in 2011.Following the acquisition of Novexel in 2010 we are working withForest on future joint global development programmes, includingCAZ AVI (a combination of ceftazidime and avibactam, formerlyknown as CAZ104) and CXL (a combination of ceftaroline andavibactam, formerly known as CXL104/CEF104). The CAZ AVIPhase III programme was initiated in 2011 and includes five trials toconfirm the efficacy and tolerability of CAZ AVI in adult patients withcomplicated intra-abdominal or complicated urinary tract infections.Patients with infections which are resistant to commonly usedantibiotics will also be included in the Phase III programme. CXLis in Phase II development for serious infections where coverageagainst resistant strains is required.To meet the high and growing need for new and better therapies forresistant bacterial infections we have built an anti-bacterials discoverycapability to ensure that AstraZeneca has the resources to createnovel mechanism anti-bacterials. Out of this work, a candidateanti-bacterial drug, AZD5099, with a novel mechanism of actioninvolving inhibition of bacterial DNA gyrase, started single ascendingdose Phase I studies in healthy volunteers in June. We are also activelyevaluating and integrating biologics anti-bacterial modalities (MAbsand vaccines) into our overall approach to dealing with seriousbacterial infection challenges.Influenza virusInfluenza is the most common vaccine-preventable disease in thedeveloped world. According to WHO estimates, seasonal influenzaresults in three to five million cases of severe illness and up to half amillion deaths globally each year, primarily among the elderly. Ratesof infection are highest among children, with school-aged childrensignificantly contributing to the spread of the disease.Our focusOur key marketed productsFluMist is a trivalent live, attenuated nasally delivered vaccineapproved for the prevention of disease caused by influenza virussubtypes A and B in eligible children and adults. FluMist is nowapproved for eligible individuals in seven countries including the US,Canada and Brazil.In February 2011, the European Commission granted marketingauthorisation to Fluenz (the trade name for FluMist in the EU), for theprevention of seasonal influenza for children 24 months to less than18 years of age. The decision is applicable to the 27 EU memberstates and the European Economic Area. It is expected that the Fluenzvaccine will be initially available in select European markets for the2012/2013 influenza season.Business ReviewAstraZeneca Annual Report and Form 20-F Information 2011Therapy Area Review Infection 65
Page 1 and 2:
healthAstraZeneca Annual Reportand
Page 3 and 4:
Financial summary$33.6bnSales down
Page 5 and 6:
China: We announcedour decision to
Page 7 and 8:
OverviewOperational overview7979 pr
Page 9 and 10:
Chairman’s StatementI would like
Page 11 and 12:
Chief Executive Officer’s ReviewA
Page 13 and 14:
The process of getting a drug to ma
Page 15 and 16: OverviewnovationInnovation drives p
Page 17 and 18: Our Strategy and PerformanceMore pe
Page 19 and 20: Using the full range of innovative
Page 21 and 22: Our strategyMissionto make the most
Page 23 and 24: Our strategic priorities to 2014Our
Page 25 and 26: Our performance in 2011Our performa
Page 27 and 28: Business shapePeopleResponsible bus
Page 29 and 30: Strategy and PerformanceaborationIm
Page 31 and 32: Delivering our strategyOur strategy
Page 33 and 34: Development projects20112010 129342
Page 35 and 36: Investing in capabilitiesA core com
Page 37 and 38: Patent expiries for our key markete
Page 39 and 40: our Established Markets footprint i
Page 41 and 42: Product qualityWe are committed to
Page 43 and 44: We have a global approach, supporte
Page 45 and 46: ComplianceWe ensure a culture of et
Page 47 and 48: tegrityBusiness ReviewWe are dedica
Page 49 and 50: Delivering our strategyResponsible
Page 51 and 52: India has the fastest growing numbe
Page 53 and 54: ProtestsAstraZeneca acknowledges th
Page 55 and 56: Also in 2011, the DIHR in collabora
Page 57 and 58: healthcollaborationRaising breast c
Page 59 and 60: Pipeline by Therapy Area at 31 Dece
Page 62 and 63: Therapy Area ReviewIn September, we
Page 64 and 65: Therapy Area ReviewGastrointestinal
Page 68 and 69: Therapy Area ReviewIn the pipelineI
Page 70 and 71: Therapy Area ReviewOur financial pe
Page 72 and 73: Therapy Area ReviewOncologyTherapy
Page 74 and 75: Therapy Area Reviewendpoints of pro
Page 76 and 77: Therapy Area ReviewOur financial pe
Page 78 and 79: healthinnovationReducing the number
Page 80 and 81: Geographical ReviewUSAstraZeneca is
Page 82 and 83: Geographical ReviewEmerging Markets
Page 84 and 85: Disciplined execution of our strate
Page 86 and 87: Financial ReviewMeasuring performan
Page 88 and 89: Financial ReviewResults of operatio
Page 90 and 91: Financial ReviewFinancial position
Page 92 and 93: Financial ReviewCapitalisation and
Page 94 and 95: Financial ReviewResults of operatio
Page 96 and 97: Financial ReviewSensitivity analysi
Page 98 and 99: Financial Reviewover the performanc
Page 100 and 101: healthcollaborationFighting the ris
Page 102 and 103: Board of Directors and Senior Execu
Page 104 and 105: Board of Directors and Senior Execu
Page 106 and 107: Corporate Governance ReportOperatio
Page 108 and 109: Corporate Governance ReportThe Boar
Page 110 and 111: Corporate Governance ReportDuring 2
Page 112 and 113: Corporate Governance ReportBusiness
Page 114 and 115: Corporate Governance ReportPolitica
Page 116 and 117:
Directors’ Remuneration ReportDav
Page 118 and 119:
Directors’ Remuneration ReportVar
Page 120 and 121:
Directors’ Remuneration ReportAdd
Page 122 and 123:
Directors’ Remuneration ReportSum
Page 124 and 125:
Directors’ Remuneration ReportSum
Page 126 and 127:
Directors’ Remuneration ReportIn
Page 128 and 129:
Directors’ Remuneration ReportPer
Page 130 and 131:
Directors’ Remuneration ReportGai
Page 132 and 133:
RiskManagement reporting and assura
Page 134 and 135:
RiskCommercialisation and business
Page 136 and 137:
RiskCommercialisation and business
Page 138 and 139:
RiskSupply chain and delivery risks
Page 140 and 141:
RiskEconomic and financial risks co
Page 142 and 143:
Financial StatementsPreparation of
Page 144 and 145:
Financial StatementsConsolidated St
Page 146 and 147:
Financial StatementsConsolidated St
Page 148 and 149:
Financial StatementsGroup Accountin
Page 150 and 151:
Financial StatementsProperty, plant
Page 152 and 153:
Financial StatementsNotes to the Gr
Page 154 and 155:
Financial Statements3 Finance incom
Page 156 and 157:
Financial Statements4 Taxation cont
Page 158 and 159:
Financial Statements6 Segment infor
Page 160 and 161:
Financial Statements9 Intangible as
Page 162 and 163:
Financial Statements10 Other invest
Page 164 and 165:
Financial Statements15 Financial in
Page 166 and 167:
Financial Statements15 Financial in
Page 168 and 169:
Financial Statements18 Post-retirem
Page 170 and 171:
Financial Statements18 Post-retirem
Page 172 and 173:
Financial Statements20 Share capita
Page 174 and 175:
Financial Statements23 Financial ri
Page 176 and 177:
Financial Statements23 Financial ri
Page 178 and 179:
Financial Statements24 Employee cos
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Financial Statements25 Commitments
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Financial Statements26 LeasesTotal
Page 194 and 195:
Financial StatementsIndependent Aud
Page 196 and 197:
Financial StatementsCompany Account
Page 198 and 199:
Financial Statements4 ReservesShare
Page 200 and 201:
Financial StatementsGroup Financial
Page 202 and 203:
Development PipelineNCEsPhase III/R
Page 204 and 205:
Development PipelineNCEsPhases I an
Page 206 and 207:
Shareholder Information> For shares
Page 208 and 209:
Shareholder InformationDocuments on
Page 210 and 211:
Corporate InformationHistory and de
Page 212 and 213:
GlossaryThe following abbreviations
Page 214 and 215:
Index2011 performance summary 23Acc
Page 216:
Contact informationRegistered offic
show all

AstraZeneca Annual Report and Form 20-F Information 2011

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?